Contemporary Considerations in Multiple Sclerosis Treatment:
A Post-Pandemic Educational Curriculum

Release Date: January 10, 2023

Valid for Credit through: January 10, 2024

This activity is jointly provided by The Consortium of Multiple Sclerosis Centers (CMSC) and Catamount Medical Education.

This activity is supported by independent educational grants from
Biogen and Bristol Myers Squibb.

Target Audience

MS specialists, general neurologists, nursing professionals, pharmacists, physician assistants, and patient advocates in the care of people living with multiple sclerosis (MS).

Learning Objectives

At the conclusion of this activity, participants should be better able to:

  • Discuss evidence-based treatment decision-making related to early treatment initiation and its impact on patient outcomes
  • Review key efficacy and safety data for available disease-modifying therapies (DMTs) when making early treatment decisions
  • Utilize treatment- and patient-specific considerations, along with patient preferences, in making initial and subsequent therapy decisions
  • Examine the mechanisms of action of DMTs and the clinical implications of their effects on the immune system
  • Review evidence and recommendations related to DMTs and vaccine response, including to COVID-19 vaccines, in people with MS

Robert K. Shin, MD, FANA, FAAN
Professor, Department of Neurology
MedStar Georgetown University Hospital
Washington, D.C.


In support of improving patient care, this activity has been planned and implemented by The Consortium of Multiple Sclerosis Centers (CMSC) and Catamount Medical Education. CMSC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the health care team.

Credit Designation

The CMSC designates this enduring activity for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The CMSC designates this activity for a maximum of 1.25 NCPD credit (1.25 in the area of pharmacology).

This knowledge-based activity, UAN JA4008165-9999-22-042-H01-P, qualifies for 1.25 contact hours (0.125 CEUs) of continuing pharmacy education credit.

All other healthcare professionals completing this course will be issued a statement of participation.

Disclosures of Conflicts of Interest Policy
It is the policy of The Consortium of Multiple Sclerosis Centers (CMSC) to ensure balance, independence, objectivity, and scientific rigor in all educational activities. All faculty, planning committee members, content reviewers, and staff participating in this activity have disclosed any relevant financial relationships they or their significant other have had within the previous 12 months with manufacturers of any commercial products/devices and/or providers of commercial services included in this educational activity. The intent of this disclosure is not to prevent a person with a relevant financial relationship from participating in the activity, but rather to provide participants with information on which they can base their own judgments. All presentations were reviewed by an independent clinician with no relevant financial relationships for the purpose of resolution of any identified conflict of interest and a determination of evidence-base and fair balance.

Faculty Disclosures

Robert K. Shin, MD, FANA, FAAN
Consulting Fees: Alexion, Biogen, Bristol Myers Squibb, Genentech, Genzyme, Horizon, Mallinckrodt, Novartis Pharmaceuticals Corporation, Roche Speakers Bureau: Alexion, Biogen, Bristol Myers Squibb, Genentech, Genzyme, Horizon, Novartis Pharmaceuticals Corporation.

Activity Staff Disclosures
June Halper, MSN, APN-C, MSCN, FAAN, and Laurie Scudder, DNP, NP, served as planners and reviewers and have disclosed no relevant financial relationships.

All other planners, reviewers, staff, or other members of the Continuing Professional Education Committee at The Consortium of Multiple Sclerosis Centers who control content have disclosed no relevant financial relationships.

The planners, reviewers, editors, staff, CE committee, or other members at Catamount Medical Education who control content have disclosed no relevant financial relationships.

How to Participate in this Activity and Obtain CE Credit

There are no fees for participating and receiving credit for this activity. During the period that the activity is available for credit, participants must:

  1. Read the CE information
  2. Complete the pre-test
  3. View the content
  4. Complete the post-test and the evaluation form.

A score of 75% correct must be achieved on the post-test to successfully complete the activity. If you do not receive a passing score, you will receive a message notifying you that you did not pass the post-test. You may retake the post-test until successful. Upon completion of the evaluation, your certificate will be emailed to you.

Our Policy on Privacy
The Consortium of Multiple Sclerosis Centers and Catamount Medical Education, LLC, respect your privacy. All personal information that is provided to Catamount Medical Education, LLC, is protected and will not be sold to a third party for commercial purposes. All personally identifiable information contained in the Catamount Medical Education, LLC, registration databases is treated as confidential and will be used only for the purposes stated in this policy, except where required by law. Catamount Medical Education, LLC, maintains user databases that contain mailing and user profile information as well as a record of the CME activities viewed and the post-test and evaluation results for CE credit. This information is provided to activity collaborators for the purposes of CE recordkeeping. By participating in this activity, you agree that Catamount Medical Education, LLC, has full permission to provide this information.

Catamount Medical Education, LLC, safeguards against the loss, misuse, or alteration of information that we have collected in this activity.

Disclosure of Unlabeled Use
CMSC and Catamount Medical Education require CE faculty (speakers) to disclose to the attendees when products or procedures being discussed are off-label, unlabeled, experimental, and/or investigational (not FDA approved); and any limitations on the information that is presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. If you have questions, contact the medical affairs department of the manufacturer for the most recent prescribing information.

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Contact Information
For questions about this activity, please contact Catamount Medical Education at [email protected].

About Me

The Continuing Medical Education Program is an integral part of the organization’s overall mission which aims to improve learners’ competence and performance‐in‐practice and ultimately improve patient outcomes.

Related Posts